WebSep 28, 2024 · Kytopen raised $30000000 on 2024-09-28 in Series A. Northpond Ventures Northpond Ventures is a private equity and venture capital that focuses on science-driven projects in life sciences and technology. http://new.kytopen.com/
Accelerating the pace of engineered cell therapies, from lab to …
WebJun 16, 2024 · Kytopen ., a transformative biotechnology company offering non-viral delivery that links the discovery, development and manufacturing of engineered cell therapies, today announced it was awarded a SBIR Fast Track grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institute of Health (NIH). WebMar 23, 2024 · About Kytopen Kytopen is a startup, spun out of MIT that has developed a proprietary Flowfect® technology for non-viral delivery of molecules into hard-to-transfect immune cells. The scalable Flowfect® technology platform uses electro-mechanical energy to deliver genetic payloads to cells in order to augment their functionality. our family wizard moments
Annual Report on Kytopen
WebMar 23, 2024 · NEWARK, NJ, March 23, 2024 – BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, announces its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). WebKytopen has raised a total of $37.1M in funding over 10 rounds. Their latest funding was raised on Sep 28, 2024 from a Series A round. Kytopen is funded by 13 investors. TBD … WebSep 28, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Kytopen Corp., a biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, today announced it has raised $30 million in an oversubscribed Series A funding.The new capital will be used to commercialize Kytopen’s Flowfect® Tx for cGMP-compliant cell therapy … roe vs wade law overturning